18 and older, any sex, with Mycoses. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
C Reactive Protein Levels in mg/L (CRP) on Posaconazole Concentrations in mg/LPrimary· 6 months after start of treatment
Posaconazole drug exposure during treatment in different stages of inflammation. To determine the differences in concentrations between patients a random additive effect was used. Additionally, to correct for differences in intervals between observations a first-order autoregressive correlation was used. The Wald type III test was used to assess the influence of inflammation on posaconazole concentration.
Posaconazole concentration
Group
Value
95% CI
Posaconazole
1.8
1 – 2.9
C reactive protein
Group
Value
95% CI
Posaconazole
23.5
5 – 75
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events (AEs) were evaluated from the start of the treatment up to 1 year..
Reporting threshold: 2%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT03760445 — HDM201 Added to CT in R/R or Newly Diagnosed AML
· Phase 1, PHASE2
· withdrawn
NCT02805946 — Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections
· Phase 4
· completed
NCT01200355 — Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergo
· Phase 4
· completed
Other University Medical Center Groningen trials
Trials by the same sponsor.
NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
· not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy
· Phase 2
· not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients
· Phase 4
· not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation
· not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra
· NA
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 6 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02492802.